Nexalin Technology (NXL) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for its patent application titled “Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder, OUD, and Substance Use Disorder, SUD.” This newly allowed patent covers Nexalin’s proprietary Deep Intracranial Frequency Stimulation, DIFS, technology, a non-invasive, drug-free approach designed to support individuals struggling with substance use disorder, including opioid use disorder, alcohol use disorder, and stimulant addiction, such as cocaine and methamphetamine use disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin Technology announces initiation of patient recruitment in UCSD study
- Nexalin Technology appoints Wesley Clark to Military, Government Advisory Board
- Nexalin Technology’s HALO Clarity headset approved for use in trials by UCSD
- Nexalin appointed industry co-chair of National TBI Registry Coalition
- Nexalin Technology announces publication of study of DIFS technology